X
[{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Announces \u00a327.5 M Extended Series A Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OMass Therapeutics"},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta and Daewoong collaborate with AffyXell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo taps Mogrify for off-the-shelf CAR-Treg project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mogrify"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Camallergy"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the partnership, Camallergy's innovative therapies is combined with OnDosis' cutting-edge Dosage Manager device technology to address the challenges physicians face in offering oral immunotherapy.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
OnDosis
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
November 29, 2023
Details:
Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.
Lead Product(s):
CAR-Treg cell therapy
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Sangamo Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
April 21, 2020
Details:
Proceeds from this financing will allow the Company to progress a pipeline of small molecule therapeutics for patients suffering from immunological and genetic disorders.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Syncona
Deal Size: $53.6 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
February 17, 2020
Details:
License agreement to utilise Affimer® proteins in next generation cell and gene therapies.
Lead Product(s):
Stefin A
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AffyXell Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
February 03, 2020